1 in which they investigated whether smoking is independently associated with recanalization and better functional outcome in patients treated with tissue-type plasminogen activator. They concluded that smokers had a better response to tissue-type plasminogen activator than nonsmokers. In the past decade, several studies have been published regarding this smoking-thrombolysis paradox.
studies with different inclusion criteria with possible selection bias, various definitions of smoking, and data collection. Third, we split the patient group into current smokers versus nonsmokers. In the non-smokers group, ex-smokers were included because of records of pack-years smoking were not available in all articles. This is a heterogeneous group, unfortunately a specific analysis of pack-years and functional outcome was not possible.
In summary, this meta-analysis suggests that smokers who receive tissue-type plasminogen activator with acute stroke had a better functional outcome versus nonsmokers. However, we agree with Kufner et al 1 that smoking is an important risk factor for stroke and that no stroke is always better than a recanalized stroke.
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